Anti-SARS-CoV-2 vaccines in recipient and/or donor before allotransplant

eJHaem

article

Maxime Jullien¹  Marianne Coste-Burel²  Beatrice Clemenceau³  Valentin Letailleur¹  Thierry Guillaume¹  Pierre Peterlin¹  Alice Garnier¹  Amandine Le Bourgeois¹  Berthe-Marie Imbert²  Jocelyn Ollier³  Audrey Grain³  Cyrille Touzeau¹  Philippe Moreau¹  Marie C Béné³  Henri Vié³  Patrice Chevallier¹ 

[1] Hematology Clinic, Nantes University Hospital;Virology Department, Nantes University Hospital;Inserm 1232, CRCINA, Nantes University;Hematology Biology, Nantes University Hospital

关键词: allogeneic;    cellular response;    COVID-19;    hematological;    humoral response;    SARS-CoV-2 mRNA;    vaccine;   

DOI  :  10.1002/jha2.398

来源: Wiley

【 摘 要 】

The impact of pre-transplant anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in 20 recipients of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and/or their donors is reported here, showing that the persistence of anti-SARS-CoV-2 antibodies can be detected in almost all patients, whatever the type of vaccine used, and up to 9 months post transplant. Also, an anti-SARS-CoV-2 spike glycoprotein CD3+ T-cell response could be detected in six (35%) of 17 evaluable patients. This study provides a rationale to consider anti-SARS-CoV-2 vaccination of both recipients and donors before Allo-HSCT.

【 授权许可】

Unknown